ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Connecticut » Pulmonary Disease

Top Pulmonary Disease Prescribers in Connecticut

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
YOUNUS MASIH M.D.

Pulmonary Disease

25,511

$1.89M

677
590 are 65+

17%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 64%

$74
Average prescription price

Avg: $170

KANAGARATNAM JEGATHESAN MD

Pulmonary Disease

11,793

$778K

462
433 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

29%
prescriptions for brand name drugs

Avg: 64%

$66
Average prescription price

Avg: $170

JOHN RODGERS MD

Pulmonary Disease

8,524

$816K

646
553 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

36%
prescriptions for brand name drugs

Avg: 64%

$96
Average prescription price

Avg: $170

DAVID GRISE MD

Pulmonary Disease

7,681

$791K

549
471 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

35%
prescriptions for brand name drugs

Avg: 64%

$103
Average prescription price

Avg: $170

M YEKTA MD

Pulmonary Disease

6,720

$567K

377
261 are 65+

7%
patients receiving schedule two controlled substances

Avg: 1%

10%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 64%

$84
Average prescription price

Avg: $170

FIELDING JOHNSON M.D.

Pulmonary Disease

6,713

$587K

266
168 are 65+

15%
patients receiving schedule two controlled substances

Avg: 1%

9%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

30%
prescriptions for brand name drugs

Avg: 64%

$87
Average prescription price

Avg: $170

MADHU GOWDA M.D.

Pulmonary Disease

5,177

$410K

392
334 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

33%
prescriptions for brand name drugs

Avg: 64%

$79
Average prescription price

Avg: $170

RICHARD KRINSKY DO

Pulmonary Disease

5,173

$969K

465
361 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

72%
prescriptions for brand name drugs

Avg: 64%

$187
Average prescription price

Avg: $170

MICHAEL PARKER MD

Pulmonary Disease

4,433

$445K

321
289 are 65+

4%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

38%
prescriptions for brand name drugs

Avg: 64%

$100
Average prescription price

Avg: $170

MICHAEL GENOVESI M.D.

Pulmonary Disease

4,132

$408K

363
328 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

44%
prescriptions for brand name drugs

Avg: 64%

$99
Average prescription price

Avg: $170

DONALD MCNICOL MD

Pulmonary Disease

3,454

$200K

268
225 are 65+

6%
patients receiving schedule two controlled substances

Avg: 1%

5%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 64%

$58
Average prescription price

Avg: $170

KAISER TOOSY MD

Pulmonary Disease

3,169

$577K

363
303 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

68%
prescriptions for brand name drugs

Avg: 64%

$182
Average prescription price

Avg: $170

ROBERT SHEIMAN MD

Pulmonary Disease

2,924

$198K

135
98 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

12%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

32%
prescriptions for brand name drugs

Avg: 64%

$68
Average prescription price

Avg: $170

DAVID BUSHELL MD

Pulmonary Disease

2,849

$294K

266
217 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

50%
prescriptions for brand name drugs

Avg: 64%

$103
Average prescription price

Avg: $170

LAWRENCE GLAUBIGER M.D.

Pulmonary Disease

2,836

$636K

267
207 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 64%

$224
Average prescription price

Avg: $170

JONATHAN GORDON M.D.

Pulmonary Disease

2,681

$255K

194
180 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

34%
prescriptions for brand name drugs

Avg: 64%

$95
Average prescription price

Avg: $170

MURUGESAPILLAI GANESAN MD

Pulmonary Disease

2,626

$163K

200
184 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 64%

$62
Average prescription price

Avg: $170

BRETT GERSTENHABER MD

Pulmonary Disease

2,620

$630K

351
304 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

73%
prescriptions for brand name drugs

Avg: 64%

$240
Average prescription price

Avg: $170

DAVID WASSERSTEIN MD

Pulmonary Disease

2,494

$554K

324
259 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

76%
prescriptions for brand name drugs

Avg: 64%

$222
Average prescription price

Avg: $170

DONNA ROMITO DO

Pulmonary Disease

2,473

$500K

286
223 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

55%
prescriptions for brand name drugs

Avg: 64%

$202
Average prescription price

Avg: $170

ROBERT KELTNER MD

Pulmonary Disease

2,404

$451K

263
213 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 64%

$188
Average prescription price

Avg: $170

MICHAEL IMEVBORE M.D.

Pulmonary Disease

2,356

$633K

390
292 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

70%
prescriptions for brand name drugs

Avg: 64%

$269
Average prescription price

Avg: $170

MOHAMMED ANWAR MD

Pulmonary Disease

2,308

$1.11M

296
245 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

64%
prescriptions for brand name drugs

Avg: 64%

$482
Average prescription price

Avg: $170

RICHARD GIOSA MD

Pulmonary Disease

2,298

$443K

292
236 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

69%
prescriptions for brand name drugs

Avg: 64%

$193
Average prescription price

Avg: $170

ERIC GENTRY MD

Pulmonary Disease

2,276

$303K

224
192 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 1%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

51%
prescriptions for brand name drugs

Avg: 64%

$133
Average prescription price

Avg: $170

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank